Signostics is a biotech medical device startup with a mission to revolutionize medical practice through portable ultrasound technology. The company's flagship product, Signos, offers healthcare professionals the ability to seamlessly integrate ultrasound into their clinical routines. This pocket-sized ultrasound platform is designed to be as convenient as a stethoscope, altering the landscape of medical practice much like handheld devices transformed various industries.
Founded in 2005 in Adelaide, Australia, Signostics ventured into the U.S. market in 2008, focusing on the development of rapid and cost-effective point-of-care medical devices. The company entered the veterinary market in January 2009 and garnered regulatory approvals to penetrate the human medical device sector in the United States, Europe, and Australia by May 2009. With offices in Palo Alto, California, and Adelaide, South Australia, Signostics strategically operates in key global locations.
The startup secured a noteworthy $5.00M Series B investment on 07 April 2010 from an impressive consortium of investors, including Brandon Capital Partners, BridgeLane Capital, Terra Rossa Capital, and Playford Capital. This backing underscores the confidence of established venture capital entities in Signostics' innovative approach to advancing medical technology.
Overall, Signostics' pioneering portable ultrasound technology holds great promise in transforming healthcare practice, and the substantial investment signifies its potential to make a lasting impact in both the medical and biotechnology sectors.
